Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disease affecting approximately 4,000 Canadians, with no effective treatments to date. Disease heterogeneity continues to limit biomarker discovery and therapeutic development.
CAPTURE ALS (Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS) is a national, multi-site platform generating deeply phenotyped, longitudinal clinical data and multimodal biospecimens from ALS patients and healthy controls. By integrating clinical, imaging, and multi-omic datasets, it enables high-resolution patient stratification and accelerates translational research across academia and industry.
Building on the success of CAPTURE ALS 1.0, the next phase, CAPTURE ALS 2.0, aims to expand sites, participants, and advanced data modalities, including neuroimaging, genomics, wearable technologies, and multi-omic profiling.
We are currently seeking Quebec-based industry partners for the CQDM–Brain Canada initiative. This is a unique opportunity to access a high-quality national platform, integrate proprietary technologies or assessments into the protocol, and accelerate biomarker and therapeutic development.
Learn more:
https://captureals.ca/
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0332430
We would greatly appreciate an indication of interest by April 30.
For more information: sophie.dahan@mcgill.ca
